SELECTED PUBLICATIONS

  1. Bansode RR, Huang W, Roy SK, Mehta KD (2008) Protein kinase Cβ deficiency increases fatty acid oxidation and reduces fat storage. J. Biol. Chem. 283:231-236. (featured on the cover of JBC, as well as selected for 2009 Annual Meeting Compendium: New Metabolism).

  2. Huang W, Bansode R, Mehta KD (2009) Loss of protein kinase Cβ protects mice against diet-induced obesity, hepatic steatosis and insulin resistance. Hepatology 49:1525-1536.  

  3. Huang W, Bansode R, Bal N, Mehta KD (2012) Ablation of PKCβ attenuates obesity syndrome of ob/ob mice by promoting WAT remodeling. J. Lipid Res. 53: 368-378.

  4. Patergnani S, Marchi S, Rimessi A, Bonora M, Mehta KD, Pinton P (2013) The protein kinase Cβ and the mitochondrial axis as key regulators of autophagy. Autophagy 9: 1367-1385.

  5. Huang W, Mehta KD (2015) Modulation of hepatic PKCβ in metabolic adaptation to a lithogenic diet.  Cell. Mol. Gastroenter. Hepatol. 1:395-405 (accompanied by an editorial by Dr. John Chiang on this work).

  6. Huang W, Mehta D, Sif S, Kent LN, Jacob ST, Ghoshal K, Mehta KD (2017) Dietary fat/cholesterol-sensitive PKCβ-RB signaling: Potential role in NASH/HCC axis. Oncotarget 8:73757-73765. (Paper was featured in the Nutrition Frontiers, a publication of NSRG, NCI, NIH).

  7. Shu Y, Hassan F, Coppola V, Baskin KK, Han H, Mehta NK, Ostrowski M, Mehta KD (2021) Hepatocyte-specific PKCβ deficiency protects against high-fat diet-induced non-alcoholic hepatic steatosis. Mol. Metab. 44:e101133. http://doi.org/10.1016/j.molmet.2020.101133.

  8. Shu Y, Hassan F, Ostrowski M, Mehta KD (2021) Role of hepatic PKCβ in nutritional regulation of hepatic glycogen synthesis. JCI Insight, 6(19):e149023.http://doi.org/10.1172/jci.insight.149023.

  9. Mehta KD (2022) A novel PKCβ inhibitor more potent than ruboxistaurin: Potential therapeutic tool for obesity and fatty liver disease. FASEB J. 36:R1984 (https://doi:org/10.1096/fasebj.2022.36.S1.R1984).

  10. Shu Y, Gumma N, Hassan F, Branch DA, Baer LA, Ostrowski MC, Stanford KI, Baskin KK, Mehta KD (2023) Hepatic PKCβ deficiency mitigates late-onset obesity. J. Biol. Chem., 299:104917

RECENT CONFERENCE PRESENTATIONS

  1. Mehta KD (2022) Preclinical efficacy of INST3399, a synthetic novel PKCβ inhibitor for treatment of obesity and fatty liver disease. June 14-16, 2022. NUTRITION 2022 LIVE ONLINE.

  2. McCarthy F, Mehta KD (2022) Identification of a novel bisindolylmaleimide derivative with potent PKCβ inhibition than ruboxistaurin with implications for obesity. International Conference on Fatty Liver, April 28-30, 2022, Vienna, Austria.

  3. Mehta KD (2022) A novel PKCβ inhibitor more potent than ruboxistaurin: Potential therapeutic tool for obesity and fatty liver disease. Experimental Biology 2022, April 2-5, 2022, Philadelphia, PA.

  4. Yaoling S, Hassan F, Sanford K, Ostrowski M, Baskin K, Mehta KD (2019) Hepatic protein kinase Cβ regulates liver cross-talk with peripheral tissues for controlling energy expenditure. Nature: Advances in Metabolic Communication. October 14-18, 2019, Rio de Janeiro, Brazil.

  5. Hassan F, Yaoling S, Coppola V, Stanford K, Baskin K, Ostrowski M, Mehta KD (2019) Hepatic protein kinase Cβ deficiency protects from high-fat diet induced obesity and hepatic steatosis. Integrated Pathways of Disease in NASH and NAFLD. Keystone Symposia, January 20-24, 2019, Santa Fe, New Mexico.